EcoDrugPlus

Neuronal Acetylcholine Receptor Subunit Alpha-7

Ensembl ID : ENSLCAG00010021054
Gene Symbol: LOC108887855
3 Cross references
205 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7

Ensembl ID : ENSLCAG00010022855
Gene Symbol: LOC108889675
3 Cross references
182 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSLCAG00010019631
Gene Symbol: NPY2R
1 Cross references
184 Possible Orthologues:

Neuropeptide Y Receptor Y2, Like

Ensembl ID : ENSLCAG00010006736
Gene Symbol: LOC108874718
4 Cross references
176 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSLCAG00010000926
Gene Symbol: NTSR1
4 Cross references
202 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSLCAG00010028330
Gene Symbol: NTRK2
1 Cross references
207 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSLCAG00010024984
Gene Symbol: NTRK3
1 Cross references
202 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSLCAG00010027075
Gene Symbol: NTRK3
4 Cross references
192 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSLCAG00010001325
Gene Symbol: LOC108899467
4 Cross references
199 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSLCAG00010002974
Gene Symbol: NTRK2B
1 Cross references
207 Possible Orthologues:

Nfe2 Like Bzip Transcription Factor 2a

Ensembl ID : ENSLCAG00010016249
Gene Symbol: NFE2L2A
4 Cross references
216 Possible Orthologues:

Nicastrin

Ensembl ID : ENSLCAG00010000954
Gene Symbol: NCSTN
2 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).